Skip to main content
Log in

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

While expression of estrogen receptor (ER) and/or progesterone receptor (PgR) predict for the efficacy of endocrine therapy and Her-2/neu overexpression/amplification predict (imperfectly) for the efficacy of treatment with trastuzumab, neither of these markers has proved effective at predicting antitumor response to other therapies. Overexpression/amplification of Her-2/neu has been one of the most extensively studied predictive parameters, but results have been controversial. In the present article we attempt to review articles published in peer-reviewed medical journals to summarize the evidence concerning Her-2/neu as a predictive factor for the efficacy of endocrine and chemotherapy, respectively. In addition, general limitations of published studies, encouraged and discouraged practices resulting from the available data and future directions which will clarify the role of Her-2/neu as a predictive parameter will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pietras RJ, Arboleda J, Reese DM, Wongripat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446, 1995

    Google Scholar 

  2. Read LD, Keith Jr D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947–3951, 1990

    Google Scholar 

  3. Antoniotti S, Maggiora P, Dati C, De Bortoli M: Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318–321, 1992

    Google Scholar 

  4. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431–437, 1991

    Google Scholar 

  5. Witters LM, Kumar R, Chinchilli VM, Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1–5, 1997

    Google Scholar 

  6. Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W: Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol 23: 70–75, 2002

    Google Scholar 

  7. Fehm T, Maimonis P, Katalinic A, Jager WH: The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55: 33–38, 1998

    Google Scholar 

  8. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigne SP, Berry DA, Younger J, Panasci LL, Millard F, Dnggan DB, Norton L, Henderson IC: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703–2711, 2001

    Google Scholar 

  9. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nelin CM, DuganM, CarneyW, Allard J: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467–1472, 2002

    Google Scholar 

  10. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, Robertson JF: Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40: 251–255, 1996

    Google Scholar 

  11. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S, Hayes DF: Prediction of response to antiHer-2/neu as predictive marker S83 estrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525, 1997

    Google Scholar 

  12. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266, 1995

    Google Scholar 

  13. Elledge RM, Green S, Ciocca D, Pagh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7–12, 1998

    Google Scholar 

  14. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW: Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79: 1220–1226, 1999

    Google Scholar 

  15. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CH: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992

    Google Scholar 

  16. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A: 1018–1023, 1993

    Google Scholar 

  17. Jukkola A, Bloigu R, Soini Y, Savolainen ER, Holli K, Blanco G: c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 37: 347–354, 2001

    Google Scholar 

  18. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11–18, 1995

    Google Scholar 

  19. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11: 43–48, 1997

    Google Scholar 

  20. Bewick M, Chadderton T, Conlon M, Lafrenie R, Morris D, Stewart D, Gluck S: Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 24: 377–384, 1999

    Google Scholar 

  21. Bewick M, Conlon M, Gerard S, Lee H, Parissenti AM, Zhang L, Gluck S, Lafrenie RM: HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 27: 847–853, 2001

    Google Scholar 

  22. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveres B: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356–2362, 2000

    Google Scholar 

  23. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19: 1698–1706, 2001

    Google Scholar 

  24. Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD: Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells 20: 32–40, 2002

    Google Scholar 

  25. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ: Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77: 2267–2273, 1998

    Google Scholar 

  26. Kim YS, Konoplev SN, Mentemurro F, Hoy E, Smith TL, Ronden G, Champlin RE, Sahin AA, Veno NT: HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7: 4008–4012, 2001

    Google Scholar 

  27. Luftner D, Schnabel S, Possinger K: c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers 14: 55–59, 1999

    Google Scholar 

  28. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM: Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917–922, 1997

    Google Scholar 

  29. Revillion F, Hebbar M, Bonneterre J, Peyrat JP: Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 32A: 231–234, 1996

    Google Scholar 

  30. Sjostrom J, Krajewski S, Franssila K, Niskanen E, Wasenius VM, Nodling S, Reed JC, Blomqvist C: A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 78: 812–815, 1998

    Google Scholar 

  31. Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Molmstrom P, Ostenstad B, Wist E, Valvere V, Bergh J, Skiold-Petterson D, Saksela E, Blomqvist C: C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38: 535–542, 2002

    Google Scholar 

  32. Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD: Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol Z 20: 2319–2326, 2002

    Google Scholar 

  33. Wright C, Cairns J, Cantwell BJ, Cattan AR, Hall AG, Harris AL, Horne CH: Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 65: 271–274, 1992

    Google Scholar 

  34. Piccart MJ, de Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux L, Arrigo L, Cantraine F, Heuson JC: Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 62: 2501–2506, 1988

    Google Scholar 

  35. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Welmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361–1370, 1998

    Google Scholar 

  36. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Radenstam CM, Golouh R, Reed R: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049–1056, 1992

    Google Scholar 

  37. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM: Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 84: 354–359, 1999

    Google Scholar 

  38. Menard S, Valagussa, Pilotti S, Gianni L, Biganzoli E, Borecchi P, Tomasie G, Casalini P, Marubini E, Colneghi MI, Cascinelli N, Bonadanna G: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 19: 329–335, 2001

    Google Scholar 

  39. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Tembe S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88: 1456–1466, 1996

    Google Scholar 

  40. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547, 1997

    Google Scholar 

  41. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 34: 499–504, 1995

    Google Scholar 

  42. Narita T, Funahashi H, Satoh Y, Takagi H: C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97–102, 1993

    Google Scholar 

  43. Molina R, Jo J, Filella X, Zanan G, Pahisq J, Mano ZM, Farrus B, Lattre ML, Gimenez N, Hage M, Estape J, Balleste AM: C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 16: 2295–2300, 1996

    Google Scholar 

  44. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A: Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 78: 267–272, 1996

    Google Scholar 

  45. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43: 87–95, 1997

    Google Scholar 

  46. Ciocca DR, Fujimura FK, Tandon AK et al.: Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84: 1279–1282, 1992

    Google Scholar 

  47. Grunt TW, Saceda M, Martin MB et al.: Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells. Int J Cancer 63: 560–567, 1995

    Google Scholar 

  48. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63–72, 1996

    Google Scholar 

  49. Coates A, Gebski V, Bishop JF et al.: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1497, 1987

    Google Scholar 

  50. Bast Jr RC, Ravdin P, Hayes DF et al.: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865–1878, 2001

    Google Scholar 

  51. Leitzel K, Teramoto Y, Konrad K et al.: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135, 1995

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Köstler, W.J., Zielinski, C.C. Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer. Breast Cancer Res Treat 81 (Suppl 1), 73–84 (2003). https://doi.org/10.1023/A:1026329109327

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026329109327

Navigation